Screener
Charles River Laboratories CRL Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Depreciation and amortization | 134,441 | 239,871 |
| Long-lived asset impairments | 26,279 | 31,203 |
| Stock-based compensation | 42,162 | 30,184 |
| Deferred income taxes | 12,077 | (41,030) |
| Write down of inventories | 3,165 | 11,067 |
| (Gains) losses and impairments on venture capital and strategic equity investments, net | (6,936) | 12,899 |
| Gain on sale of assets | (38,484) | — |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's stock-based comp?
- Charles River Laboratories (CRL) reported stock-based comp of $19.78M in Q2 2026.
- How has Charles River Laboratories's stock-based comp changed year-over-year?
- Charles River Laboratories's stock-based comp increased by 16.0% year-over-year, from $17.05M to $19.78M.
- What is the long-term trend for Charles River Laboratories's stock-based comp?
- Over 4 years (2021 to 2025), Charles River Laboratories's stock-based comp has grown at a -0.1% compound annual growth rate (CAGR), from $71.47M to $71.08M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Charles River Laboratories's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude